Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
Trop2 ADC -01 | IND | Solid Tumor | Non-small cell lung cancer,Pancreatic cancer |
Captured Trop2 antibody on CM5 chip via anti-mouse antibodies surface can bind Rhesus macaque TROP-2 Protein, His Tag (Cat. No. TR2-R52H3) with an affinity constant of 5.48 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Sacituzumab govitecan | IMMU0132; GS-0132; IMMU-0132; IMMU-132; TROP-2-SN-38 | Approved | Trodelvy, 拓达维, TRODELVY | United States | Triple Negative Breast Neoplasms | Immunomedics Inc | 2020-04-22 | Brain metastases; Urinary Bladder Neoplasms; Klatskin Tumor; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Metastatic breast cancer; Esophageal Squamous Cell Carcinoma; Thyroid Carcinoma, Anaplastic; Endometrial Neoplasms; Thymoma; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Solid tumours; Neoplasms; Salivary Gland Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Glioblastoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Liver Failure | Details | |
Sacituzumab govitecan | IMMU0132; GS-0132; IMMU-0132; IMMU-132; TROP-2-SN-38 | Approved | Trodelvy, 拓达维, TRODELVY | United States | Triple Negative Breast Neoplasms | Immunomedics Inc | 2020-04-22 | Brain metastases; Urinary Bladder Neoplasms; Klatskin Tumor; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Metastatic breast cancer; Esophageal Squamous Cell Carcinoma; Thyroid Carcinoma, Anaplastic; Endometrial Neoplasms; Thymoma; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Solid tumours; Neoplasms; Salivary Gland Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Glioblastoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Liver Failure | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
SHR-A1921 | SHR-A1921; SHRA1921; SHR-1921 | Phase 3 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Salivary Gland Neoplasms; Breast Neoplasms; Brain metastases | Details |
OBI-992 | OBI-992 | Phase 2 Clinical | Obi Pharma Usa Inc | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
HS-20105 | HS-20105; HS20105 | Phase 2 Clinical | Hansoh BioMedical R&D Company | Solid tumours | Details |
IBI130 | IBI130; IBI-130 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
Anti TROP2 antibody drug conjugate ADC(Fudan University) | Phase 2 Clinical | Fudan University | Triple Negative Breast Neoplasms | Details | |
9MW-2921 | 9MW2921; 9MW-2921 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours | Details |
MHB036C | MHB-036C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
BAT-8008 | BAT8008; BAT-8008 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
DB-1305 | DB1305; BNT325; DB-1305; BNT-325 | Phase 2 Clinical | Solid tumours | Details | |
BIO-106 | BIO-106 | Phase 2 Clinical | Hangzhou Baikai Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
BL-M02D1 | Phase 2 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
LCB-84 | LCB-84 | Phase 2 Clinical | Legochem Biosciences Inc | Solid tumours | Details |
重组人源化抗Trop2单抗-SN38偶联物 | ESG-401; STI-3258 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
FDA018 Antibody Drug Conjugate | FDA018-ADC; FDA-018-ADC | Phase 2 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Neoplasm Metastasis | Details |
DAC-002 | DAC-002; JS-108 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma | Details |
MT-302 | MT-302 | Phase 1 Clinical | Myeloid Therapeutics Inc | Carcinoma; Colonic Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
SHR-A1921 | SHR-A1921; SHRA1921; SHR-1921 | Phase 3 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Salivary Gland Neoplasms; Breast Neoplasms; Brain metastases | Details |
OBI-992 | OBI-992 | Phase 2 Clinical | Obi Pharma Usa Inc | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
HS-20105 | HS-20105; HS20105 | Phase 2 Clinical | Hansoh BioMedical R&D Company | Solid tumours | Details |
IBI130 | IBI130; IBI-130 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
Anti TROP2 antibody drug conjugate ADC(Fudan University) | Phase 2 Clinical | Fudan University | Triple Negative Breast Neoplasms | Details | |
9MW-2921 | 9MW2921; 9MW-2921 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours | Details |
MHB036C | MHB-036C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
BAT-8008 | BAT8008; BAT-8008 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
DB-1305 | DB1305; BNT325; DB-1305; BNT-325 | Phase 2 Clinical | Solid tumours | Details | |
BIO-106 | BIO-106 | Phase 2 Clinical | Hangzhou Baikai Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
BL-M02D1 | Phase 2 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
LCB-84 | LCB-84 | Phase 2 Clinical | Legochem Biosciences Inc | Solid tumours | Details |
重组人源化抗Trop2单抗-SN38偶联物 | ESG-401; STI-3258 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
FDA018 Antibody Drug Conjugate | FDA018-ADC; FDA-018-ADC | Phase 2 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Neoplasm Metastasis | Details |
DAC-002 | DAC-002; JS-108 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma | Details |
MT-302 | MT-302 | Phase 1 Clinical | Myeloid Therapeutics Inc | Carcinoma; Colonic Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
This web search service is supported by Google Inc.